Boyd Sarita D, Maldarelli Frank, Sereti Irini, Ouedraogo G Laissa, Rehm Catherine A, Boltz Valerie, Shoemaker Diana, Pau Alice K
SAIC-Frederick, Inc., MD, USA.
Antivir Ther. 2011;16(2):257-61. doi: 10.3851/IMP1749.
Here, we describe an HIV-infected patient with pretreatment resistance to raltegravir, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, and the ultimate ability to achieve viral suppression. Pretreatment integrase resistance testing is not routinely performed because transmitted integrase mutations conferring resistance to raltegravir are currently thought to be negligible. We suggest obtaining a pretreatment integrase genotype in patients with transmitted multiclass drug resistance in order to create an optimal first regimen and increase the chance for virological suppression.
在此，我们描述了一名对拉替拉韦、核苷类逆转录酶抑制剂、非核苷类逆转录酶抑制剂和蛋白酶抑制剂存在治疗前耐药性的HIV感染患者，以及最终实现病毒抑制的能力。由于目前认为导致对拉替拉韦耐药的传播性整合酶突变可忽略不计，因此治疗前整合酶耐药性检测并非常规进行。我们建议，对于存在传播性多类药物耐药性的患者，进行治疗前整合酶基因型检测，以便制定最佳的初始治疗方案并增加病毒学抑制的机会。
